Retrospective Analysis Of The Clinical Efficacy Of Liraglutide In The Treatment Of Overweight / Obese Patients With Polycystic Ovary Syndrome

Objective: To retrospectively analyze the clinical efficacy of liraglutide in the treatment of Polycystic Ovary Syndrome(PCOS)patients with overweight / obesity.Methods: Patients with PCOS who met the admission criteria in our hospital from January 2018 to December 2019 were selected as the research objects,and were divided into metformin treatment group(44 cases in control group)and liraglutide treatment group(43 cases in study group).Analysis of relevant clinical data and changes before and after treatment in the two groups,to evaluate the improvement of related indicators and the clinical efficacy of liraglutide in the treatment of PCOS patients after 12 weeks of treatment.Results:(1)Comparison of age,BMI,body weight,glucose metabolism,sex hormones and lipid metabolism between the control group and the research group before treatment,there was no statistical difference between the two groups(P> 0.05),which was comparable.(2)Compared before and after treatment in the control group,the patient’s weight,body mass index(BMI),waist circumference,HOMA insulin resistance index(HOMA-IR),testosterone(T),free testosterone(FT),total cholesterol(TC),triglycerid es(TG),low density lipoprotein cholesterol(LDL-C)decreased,sex hormone binding globulin(SHBG),high density lipoprotein cholesterol(HDL-C)increased,the difference was statistically significant(P <0.05).(3)Compared before and after treatment in the study group,the patient’s weight,BMI,waist circumference,fasting blood glucose(FPG),2 hour postprandial blood glucose(2hPG),fasting insulin(FINS),2 hour postprandial fasting insulin(2hINS),HOMA-IR,Serum luteinizing hormone(LH)/ follicle stimulating hormone(FSH),T,FT,TG,TC,LDL-C decreased,SHBG,HDL-C increased,the difference was statistically significant(P <0.05).(4)Compared between the two groups after treatment,the body weight,BMI,2hINS,HOMA-IR,LH / FSH,T,TG levels of the study group were significantly reduced,and HDL-C levels were significantly increased,the difference was statistically significant(P <0.05).(5)The Comparison of Mean Difference between the two groups before and after treatment,body weight,BMI,waist circumference,2hPG,2hINS,T,TG,HDL-C levels of the study group Mean Difference were higher than those of the control group before and after treatment,the difference was statistically significant(P <0.05).Conclusion: Liraglutide can reduce the weight and BMI of overweight / obese patients with PCOS,and can improve glucose and lipid metabolism disorders,sex hormone levels and insulin resistance and its efficacy is better than metformin.Liraglutide is effective in treating overweight / obese patients with PCOS,and is worthy of clinical application.